Amylyx Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Amylyx Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q3 2024.
  • Amylyx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$72.7M, a 448% decline year-over-year.
  • Amylyx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$259M, a 14232% decline year-over-year.
  • Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $49.3M.
  • Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$198M, a 126% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$259M -$72.7M -$93.6M -448% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$166M -$72.7M -$94.8M -429% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$71.1M -$119M -$120M -7652% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 $49.3M $4.73M +$47.4M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 $1.84M $20.9M +$74.6M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$72.8M $22.1M +$76.1M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$149M $1.57M +$49.4M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$198M -$42.7M -$14.4M -50.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 -$184M -$53.8M -$30.6M -132% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$153M -$54.1M -$32.1M -147% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$121M -$47.8M -$33.3M -229% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$87.9M -$28.3M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$23.1M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$21.9M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$14.5M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.